|
 |
Antibacterials
Representing one of the top therapeutic categories, the antibiotics market has been estimated to have worldwide
sales of over $26 billion, despite heavy use of low-priced generic products. Six antibiotics have attained
annual sales of more than $1 billion each. The growing medical problem of drug-resistant bacteria presents a
new and expanding market opportunity. Bacterial resistance is causing many of the current antibiotics to lose
efficacy, while the pipeline of replacement products that target antibiotic resistance is remarkably thin. Paratek
is a world leader in the discovery and development of tetracycline-derived products to combat bacterial resistance
and small molecule pharmaceuticals to prevent serious bacterial infections.
Anti-Inflammatories
The worldwide pharmaceutical market for drugs targeting diseases where inflammation is a primary component exceeds
$40 billion annually. This market includes products that treat many diseases, such as asthma, arthritis, multiple
sclerosis, stroke, inflammatory bowel diseases, psoriasis and atherosclerosis. The utility of tetracyclines has
been established clinically and in a variety of studies for many of these conditions, and current tetracyclines are
chronically and substantially used for their anti-inflammatory activity in a number of diseases, including arthritis
and moderate to severe acne. Paratek is a leading company in the development of novel improved tetracycline derived
compounds with reduced or eliminated antibacterial activity for these diseases.
|
